In vivo MRI assessment of a novel GdIII-based contrast agent designed for high magnetic field applications

Contrast Media and Molecular Imaging

Volumn 3, Issue 2, 2008, Pages 78-85

  de Sousa, Paulo Loureiro ^a,b   Livramento, João Bruno ^c   Helm, Lothar ^c   Merbach, André E ^c   Même, William ^d   Doan, Bich Thuy ^a,e   Beloeil, Jean Claude ^a   Prata, Maria I M ^f   Santos, Ana C ^f   Geraldes, Carlos F G C ^g   Tóth, Éva ^a,c  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c EPFL   (Switzerland)

^d UNIVERSITÉ D'ORLÉANS   (France)

^e CNRS   (France)

^f UNIVERSITY OF COIMBRA   (Portugal)

^g UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

imaging; Biodistribution; Contrast agents; Gadolinium; High magnetic field; In vivo; Magnetic resonance imaging; Pharmacokinetics

Indexed keywords

GADOLINIUM CHELATE; GADOLINIUM DIETHYLENETRIAMINETETRACETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; SAMARIUM 153;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG STRUCTURE; GAMMA SCINTIGRAPHY; HYDROPHILICITY; KIDNEY CORTEX; KIDNEY MEDULLA; LIVER; MAGNETIC FIELD; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAXATION TIME; SINGLE DRUG DOSE; THORAX; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; GADOLINIUM; IMAGE ENHANCEMENT; KIDNEY; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 44249115823     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.233     Document Type: Article

References (24)

1. Pautler RG. Mouse MRI: Concepts and Applications in Physiology. Physiology 2004; 19: 168-175.
2. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 1999; 99: 2293-2352.
3. Merbach AE, Tóth É (eds). The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Wiley: Chichester, 2001.
4. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem. Soc. Rev. 2006; 35: 512.
5. Tóth E, Helm L, Merbach AE. Relaxivity of gadolinium(III) complexes: theory and mechanism. In The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging, Merbach AE, Tóth É (eds). Wiley: Chichester, 2001; 45-120.
6. Livramento JB, Tóth E, Sour A, Borel A, Merbach AE, Ruloff R. High relaxivity confined to a small molecular space: a metallostar-based, potential MRI contrast agent. Angew. Chem. Int. Edn 2005; 44: 1504-1508.
7. 3+ ions densely packed in a starburst-shaped heterometallic compound. Chem. Eur. J. 2006; 12: 989-1003.
8. Livramento JB, Weidensteiner C, Prata MIM, Allegrini PR, Geraldes CFGC, Helm L, Kneuer R, Merbach AE, Santos AC, Schmidt P, Tóth É. First in vivo MRI assessment of a self-assembled metallostar compound endowed with a remarkable high field relaxivity. Contrast Media Mol. Imag. 2006; 1: 30-40.
9. III complex: towards the optimization of relaxivity for MRI contrast agent applications at high magnetic field. Dalton Trans. 2008; 1195.
10. Brücher E, Sherry AD. Stability and toxicity of contrast agents. In The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging, Tóth E, Merbach AE (eds). Wiley: Chichester, 2001; 243.
11. III polyaminocarboxylates with a rigid xylene core display remarkable proton relaxivities. Inorg. Chem. 2005; 44: 4747-4755.
12. Paul-Roth C, Raymond KN. Amide functional group contribution to the stability of gadolinium(III) complexes: DTPA derivatives. Inorg. Chem. 1995; 34: 1408-1412.
13. Tweedle MF, Eaton SM, Eckelman WC, Gaughan GT, Hagan JJ, Wedeking PW, Yost FJ. Comparative chemical structure and pharmacokinetics of mri contrast agents. Invest. Radiol. 1988; 23(suppl. 1): S236-S239.
14. Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest. Radiol. 1993; 28(suppl. 1): S28-S43.
15. Baumann D, Rudin M. Quantitative assessment of rat kidney function by measuring the clearance of the contrast agent Gd(DOTA) using dynamic MRI. Magn. Res. Imag. 2000; 18: 587-595.
16. 1 relaxivity in the brain tissue in vivo is lower than in saline. Magn. Reson. Med. 2005; 53: 35-40.
17. Raghunand N, Howison C, Sherry AD, Zhang S, Gillies RJ. Renal and systemic pH-imaging by contrast-enhanced MRI. Magn. Reson. Med. 2003; 49: 249-257.
18. Shuter B, Tofts PS, Wang SC, Pope JM. The relaxivity of Gd-EOB-DTPA and Gd-DTPA in liver and kidney of the Wistar rat. Magn. Reson. Imag. 1996; 14: 243-253.
19. Pedersen M, Morkenborg J, Jensen Fr, Stodkilde-Jorgensen H, Djurhuus JC, Frokieer J. In vivo measurements of relaxivities in the rat kidney cortex. Magn. Reson. Imag. 2000; 12: 289-296.
20. Gillis A, Gray M, Burstein D. Relaxivity and diffusion of gadolinium agents in cartilage. Magn. Reson. Med. 2002; 48: 1068-1071.
21. Aime S, Botta M, Bruce JI, Mainero V, Parker D, Terreno E. Modulation of the water exchange rates in [Gd-DO3A] complex by formation of ternary complexes with carboxylate ligands. Chem. Commun. 2001; 115-116.
22. 3+ DTPA derivatives with high hepatic specificity: in vivo and in vitro studies. J. Inorg. Biochem. 2002; 91: 312-319.
23. Alves FC, Donato P, Sherry AD, Zaheer A, Zhang S, Lubag AJM, Merritt ME, Lenkinski RE, Frangioni JV, Neves M, Prata MI, Santos AC, de Lima JJ, Geraldes CF. Silencing of phosphonate-gadolinium magnetic resonance imaging contrast by hydroxya-patite binding. Invest. Radiol. 2003; 38(12): 750-760.
24. 2, and spin density. Magn. Reson. Med. 2004, 51: 661-667. [Erratum in: Magn. Reson. Med. 2004, 52: 698].